Literature DB >> 30918026

Protein Z-dependent protease inhibitor (ZPI) is a physiologically significant inhibitor of prothrombinase function.

Xin Huang1, Richard Swanson2, Heather K Kroh3, Paul E Bock3.   

Abstract

Current thought holds that factor Xa (FXa) bound in the prothrombinase complex is resistant to regulation by protein protease inhibitors during prothrombin activation. Here we provide evidence that, contrary to this view, the FXa-specific serpin inhibitor, protein Z-dependent protease inhibitor (ZPI), complexed with its cofactor, protein Z (PZ), functions as a physiologically significant inhibitor of prothrombinase-bound FXa during prothrombin activation. Kinetics studies showed that the rapid rate of inhibition of FXa by the ZPI-PZ complex on procoagulant membrane vesicles (ka (app) ∼107 m-1 s-1) was decreased ∼10-fold when FXa was bound to FVa in prothrombinase and a further ∼3-4-fold when plasma levels of S195A prothrombin were present (ka (app) 2 × 105 m-1 s-1). Nevertheless, the ZPI-PZ complex produced a major inhibition of thrombin generation during prothrombinase-catalyzed activation of prothrombin under physiologically relevant conditions. The importance of ZPI-PZ complex anticoagulant regulation of FXa both before and after incorporation into prothrombinase was supported by thrombin generation assays in plasma. These showed enhanced thrombin generation when the inhibitor was neutralized with a PZ-specific antibody and decreased thrombin generation when exogenous ZPI-PZ complex was added whether prothrombin was activated directly by FXa or through extrinsic or intrinsic pathway activators. Moreover, the PZ antibody enhanced thrombin generation both in the absence and presence of activated protein C (APC) anticoagulant activity. Taken together, these results suggest an important anticoagulant role for the ZPI-PZ complex in regulating both free FXa generated in the initiation phase of coagulation as well as prothrombinase-bound FXa in the propagation phase that complement prothrombinase regulation by APC.
© 2019 Huang et al.

Entities:  

Keywords:  coagulation factor; factor Va; factor Xa; protease; protease inhibitor; protein Z; protein Z-dependent protease inhibitor; prothrombin; prothrombinase; serpin

Mesh:

Substances:

Year:  2019        PMID: 30918026      PMCID: PMC6514612          DOI: 10.1074/jbc.RA118.006787

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Exosites determine macromolecular substrate recognition by prothrombinase.

Authors:  S Krishnaswamy; A Betz
Journal:  Biochemistry       Date:  1997-10-07       Impact factor: 3.162

2.  Direct detection of activated protein C in blood from human subjects.

Authors:  A Gruber; J H Griffin
Journal:  Blood       Date:  1992-05-01       Impact factor: 22.113

3.  Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. Kinetic behavior of two-chain factor VII in the presence and absence of tissue factor.

Authors:  S A Silverberg; Y Nemerson; M Zur
Journal:  J Biol Chem       Date:  1977-12-10       Impact factor: 5.157

4.  Role of proexosite I in factor Va-dependent substrate interactions of prothrombin activation.

Authors:  P J Anderson; A Nesset; K R Dharmawardana; P E Bock
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

5.  Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles.

Authors:  S Krishnaswamy; K C Jones; K G Mann
Journal:  J Biol Chem       Date:  1988-03-15       Impact factor: 5.157

6.  Basis for the specificity and activation of the serpin protein Z-dependent proteinase inhibitor (ZPI) as an inhibitor of membrane-associated factor Xa.

Authors:  Xin Huang; Alexey Dementiev; Steven T Olson; Peter G W Gettins
Journal:  J Biol Chem       Date:  2010-04-28       Impact factor: 5.157

7.  Characterization of the protein Z-dependent protease inhibitor.

Authors:  X Han; R Fiehler; G J Broze
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

8.  Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation.

Authors:  Daniel J D Johnson; Wei Li; Ty E Adams; James A Huntington
Journal:  EMBO J       Date:  2006-04-13       Impact factor: 11.598

Review 9.  Membranes: a meeting point for lipids, proteins and therapies.

Authors:  Pablo V Escribá; José M González-Ros; Félix M Goñi; Paavo K J Kinnunen; Lászlo Vigh; Lissete Sánchez-Magraner; Asia M Fernández; Xavier Busquets; Ibolya Horváth; Gwendolyn Barceló-Coblijn
Journal:  J Cell Mol Med       Date:  2008-02-08       Impact factor: 5.310

10.  Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C.

Authors:  J Rosing; L Hoekema; G A Nicolaes; M C Thomassen; H C Hemker; K Varadi; H P Schwarz; G Tans
Journal:  J Biol Chem       Date:  1995-11-17       Impact factor: 5.157

View more
  4 in total

1.  Engineering a protein Z-dependent protease inhibitor (ZPI) mutant as a novel antagonist of ZPI anticoagulant function for hemophilia treatment.

Authors:  Xin Huang
Journal:  J Thromb Haemost       Date:  2019-09-05       Impact factor: 5.824

Review 2.  Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.

Authors:  Steven P Grover; Nigel Mackman
Journal:  Front Cardiovasc Med       Date:  2022-05-03

3.  Impact of COVID-19 on Subclinical Placental Thrombosis and Maternal Thrombotic Factors.

Authors:  Marie Carbonnel; Camille Daclin; Morgan Tourne; Emmanuel Roux; Mathilde Le-Marchand; Catherine Racowsky; Titouan Kennel; Eric Farfour; Marc Vasse; Jean-Marc Ayoubi
Journal:  J Clin Med       Date:  2022-07-14       Impact factor: 4.964

4.  PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma.

Authors:  Yinkui Chen; Xiusheng Qiu; Donghao Wu; Xu Lu; Guanghui Li; Yongsheng Tang; Changchang Jia; Zhiyong Xiong; Tiantian Wang
Journal:  Genes (Basel)       Date:  2022-08-26       Impact factor: 4.141

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.